LINC01296/miR-26a/GALNT3 Axis Contributes to Colorectal Cancer Progression by Regulating O-glycosylated MUC1 Via PI3K/AKT Pathway

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2018 Dec 15

PMID 30547804

Citations 56

Authors

Bing Liu

Shimeng Pan

Yang Xiao

Qianqian Liu

JingChao Xu

Li Jia

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNAs (LncRNAs) emerging as pivotal marker in the procession of cancer, including colorectal cancer (CRC). Abnormal O-glycosylation is a crucial modification during cancer malignancy. The aim of this work is to analyze the alteration of O-glycosylation involved in CRC progression.

Methods: qRT-PCR is utilized to screen the differential linc01296 expression in CRC tissues and cell lines. Functionally, CRC cell proliferation, aggressiveness and apoptosis are measured through relevant experiments, including CCK8 assay, colony formation assay, transwell assay, western blot and flow cytometry. Dual-luciferase reporter gene assay and RIP assay confirm the direct interaction between linc01296 and miR-26a. The xenografts and liver metatstatic nude mice models are established to show the inner effect of linc01296.

Results: Differential expression of linc01296 is confirmed and closely correlated with the malignancy of CRC cell lines and poor clinical prognosis. Moreover, alteration of linc01296 affects CRC cell proliferation, metastasis and chemoresistance to 5-fluorouracil (5-FU) in vitro. Mechanically, linc01296 acts as a direct target of miR-26a, and thereby influenced CRC malignancy. Our investigation corroborates that linc01296 functions as an endogenous sponge of miR-26a to regulate mucin1 (MUC1) expression, catalyzed by GALNT3, which modulates the activity of PI3K/AKT pathway. Interestingly, upregulated linc01296 promotes the tumorigensis, liver metastasis and chemoresistance of CRC cell lines in vivo.

Conclusion: These new findings indicate that linc01296/miR-26a/GALNT3 axis involves in the progression of CRC cells, illuminating the possible mechanism mediated by O-glycosylated MUC1 via PI3K/AKT pathway. This work renders potential diagnostic biomarkers and prospective therapeutic targets for CRC.

Citing Articles

Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review).

Zhang X, Shi L, Xing M, Li C, Ma F, Ma Y Int J Mol Med. 2024; 55(1).

PMID: 39513614 PMC: 11573320. DOI: 10.3892/ijmm.2024.5456.

The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors.

Li P, Ma X, Gu X Front Cell Dev Biol. 2024; 12:1442193.

PMID: 39161590 PMC: 11330846. DOI: 10.3389/fcell.2024.1442193.

N-acetylgalactosaminyltransferase GALNT6 is a potential therapeutic target of clear cell renal cell carcinoma progression.

Sun L, Li Z, Shu P, Lu M Cancer Sci. 2024; 115(10):3320-3332.

PMID: 39105355 PMC: 11447896. DOI: 10.1111/cas.16296.

MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3.

Zhao A, Pan Y, Gao Y, Zhi Z, Lu H, Dong B BMC Cancer. 2024; 24(1):559.

PMID: 38702644 PMC: 11069143. DOI: 10.1186/s12885-024-12314-6.

Identification of expression profiles and prognostic value of RFCs in colorectal cancer.

Misbah M, Kumar M, Najmi A, Akhtar M Sci Rep. 2024; 14(1):6607.

PMID: 38504096 PMC: 10951252. DOI: 10.1038/s41598-024-56361-2.

References

Brockhausen I . Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1999; 1473(1):67-95. DOI: 10.1016/s0304-4165(99)00170-1. View

Woolf S . The best screening test for colorectal cancer--a personal choice. N Engl J Med. 2000; 343(22):1641-3. DOI: 10.1056/NEJM200011303432211. View

Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M . Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 2002; 94(7):1939-46. DOI: 10.1002/cncr.10423. View

Dosaka-Akita H, Kinoshita I, Yamazaki K, Izumi H, Itoh T, Katoh H . N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer. 2002; 87(7):751-5. PMC: 2364253. DOI: 10.1038/sj.bjc.6600536. View

Walsh J, Terdiman J . Colorectal cancer screening: scientific review. JAMA. 2003; 289(10):1288-96. DOI: 10.1001/jama.289.10.1288. View

Onitsuka K, Shibao K, Nakayama Y, Minagawa N, Hirata K, Izumi H . Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci. 2003; 94(1):32-6. PMC: 11160290. DOI: 10.1111/j.1349-7006.2003.tb01348.x. View

Yamamoto S, Nakamori S, Tsujie M, Takahashi Y, Nagano H, Dono K . Expression of uridine diphosphate N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase 3 in adenocarcinoma of the pancreas. Pathobiology. 2003; 71(1):12-8. DOI: 10.1159/000072957. View

Hang H, Bertozzi C . The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem. 2005; 13(17):5021-34. DOI: 10.1016/j.bmc.2005.04.085. View

Fuster M, Esko J . The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005; 5(7):526-42. DOI: 10.1038/nrc1649. View

10.

Kalra A, Campbell R . Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer. 2008; 45(1):164-73. DOI: 10.1016/j.ejca.2008.10.008. View

11.

Park J, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T . Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 2010; 70(7):2759-69. DOI: 10.1158/0008-5472.CAN-09-3911. View

12.

Gupta R, Shah N, Wang K, Kim J, Horlings H, Wong D . Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464(7291):1071-6. PMC: 3049919. DOI: 10.1038/nature08975. View

13.

Van Schaeybroeck S, Allen W, Turkington R, Johnston P . Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011; 8(4):222-32. DOI: 10.1038/nrclinonc.2011.15. View

14.

Ebi H, Corcoran R, Singh A, Chen Z, Song Y, Lifshits E . Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011; 121(11):4311-21. PMC: 3204842. DOI: 10.1172/JCI57909. View

15.

Wu Y, Liu C, Hu R, Huang M, Lee J, Chen C . Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011; 71(23):7270-9. DOI: 10.1158/0008-5472.CAN-11-1161. View

16.

Rachagani S, Torres M, Kumar S, Haridas D, Baine M, Macha M . Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. J Hematol Oncol. 2012; 5:68. PMC: 3511181. DOI: 10.1186/1756-8722-5-68. View

17.

Yang X, Zhang X, Lu X, Jia H, Liang L, Dong Q . MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 2013; 59(5):1874-85. DOI: 10.1002/hep.26941. View

18.

Wang Z, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud M . Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget. 2014; 5(2):544-60. PMC: 3964228. DOI: 10.18632/oncotarget.1652. View

19.

Lin M, Huang M, Liu C, Yang T, Huang M . GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol. 2014; 50(5):478-84. DOI: 10.1016/j.oraloncology.2014.02.003. View

20.

Cech T, Steitz J . The noncoding RNA revolution-trashing old rules to forge new ones. Cell. 2014; 157(1):77-94. DOI: 10.1016/j.cell.2014.03.008. View